A Structured Review of Antithrombotic Therapy in Peripheral Artery Disease with a Focus on Revascularization: A TASC (InterSociety Consensus for the Management of Peripheral Artery Disease) Initiative

Circulation

Volumn 135, Issue 25, 2017, Pages 2534-2555

  Hess, Connie N ^a   Norgren, Lars ^b   Ansel, Gary M ^c   Capell, Warren H ^d   Fletcher, John P ^a   Fowkes, F Gerry R ^e   Gottsäter, Anders ^f   Hitos, Kerry ^g   Jaff, Michael R ^e   Nordanstig, Joakim ^h   Hiatt, William R ^a,i  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b CPC Clinical Research   (United States)

^c Örebro University   (Sweden)

^d Ohio Health Work Health   (United States)

^e UNIVERSITY OF SYDNEY   (Australia)

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

^g LUND UNIVERSITY   (Sweden)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

antithrombotic; peripheral artery disease; revascularization

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CILOSTAZOL; CLOPIDOGREL; TICAGRELOR; TICLOPIDINE; VORAPAXAR; FIBRINOLYTIC AGENT;

ANTICOAGULANT THERAPY; ANTICOAGULATION; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; ENDOVASCULAR SURGERY; HUMAN; LEG REVASCULARIZATION; MANAGED CARE; META ANALYSIS (TOPIC); MOLECULAR PATHOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPULATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTENOSIS; REVIEW; SYSTEMATIC REVIEW (TOPIC); THROMBOSIS; CONSENSUS; DISEASE MANAGEMENT; MEDICAL SOCIETY; PATHOPHYSIOLOGY; PERIPHERAL ARTERIAL DISEASE; PROCEDURES; STANDARDS;

CLINICAL TRIALS AS TOPIC; CONSENSUS; DISEASE MANAGEMENT; FIBRINOLYTIC AGENTS; HUMANS; PERIPHERAL ARTERIAL DISEASE; SOCIETIES, MEDICAL;

EID: 85020892994     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.117.024469     Document Type: Review

References (97)

1. Hiatt WR, Goldstone J, Smith SC Jr, McDermott M, Moneta G, Oka R, Newman AB, Pearce WH, American Heart Association Writing Group 1 Atherosclerotic Peripheral Vascular Disease Symposium II: nomenclature for vascular diseases. Circulation 2008 118 2826 2829. doi: 10.1161/CIRCULATIONAHA.108.191171
2. Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, Norman PE, Sampson UK, Williams LJ, Mensah GA, Criqui MH, Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 2013 382 1329 1340. doi: 10.1016/S0140-6736(13)61249-0
3. Criqui MH, Aboyans V, Epidemiology of peripheral artery disease. Circ Res 2015 116 1509 1526. doi: 10.1161/CIRCRESAHA.116.303849
4. Nehler MR, Duval S, Diao L, Annex BH, Hiatt WR, Rogers K, Zakharyan A, Hirsch AT, Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population. J Vasc Surg 2014 60 686.e2 695.e2. doi: 10.1016/j.jvs.2014.03.290
5. Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, Fleisher LA, Fowkes FG, Hamburg NM, Kinlay S, Lookstein R, Misra S, Mureebe L, Olin JW, Patel RA, Regensteiner JG, Schanzer A, Shishehbor MH, Stewart KJ, Treat-Jacobson D, Walsh ME, 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2017 135 e726 e779. doi: 10.1161/CIR.0000000000000471
6. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007 33 S1 S75
7. Jones WS, Mi X, Qualls LG, Vemulapalli S, Peterson ED, Patel MR, Curtis LH, Trends in settings for peripheral vascular intervention and the effect of changes in the outpatient prospective payment system. J Am Coll Cardiol 2015 65 920 927
8. Hong MS, Beck AW, Nelson PR, Emerging national trends in the management and outcomes of lower extremity peripheral arterial disease. Ann Vasc Surg 2011 25 44 54. doi: 10.1016/j.avsg.2010.08.006
9. Mukherjee D, Eagle K, The importance of early diagnosis and treatment in peripheral arterial disease: insights from the PARTNERS and REACH registries. Curr Vasc Pharmacol 2010 8 293 300
10. Criqui MH, Ninomiya JK, Wingard DL, Ji M, Fronek A, Progression of peripheral arterial disease predicts cardiovascular disease morbidity and mortality. J Am Coll Cardiol 2008 52 1736 1742. doi: 10.1016/j.jacc.2008.07.060
11. Bonaca MP, Scirica BM, Creager MA, Olin J, Bounameaux H, Dellborg M, Lamp JM, Murphy SA, Braunwald E, Morrow DA, Vorapaxar in patients with peripheral artery disease: results from TRA2°P-TIMI 50. Circulation 2013 127 1522 1529. doi: 10.1161/CIRCULATIONAHA.112.000679
12. Sigvant B, Kragsterman B, Falkenberg M, Hasvold P, Johansson S, Thuresson M, Nordanstig J, Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization. J Vasc Surg 2016 64 1009.e3 1017.e3. doi: 10.1016/j.jvs.2016.03.429
13. Bonaca MP, Gutierrez JA, Creager MA, Scirica BM, Olin J, Murphy SA, Braunwald E, Morrow DA, Acute limb ischemia and outcomes with vorapaxar in patients with peripheral artery disease: results from the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50). Circulation 2016 133 997 1005. doi: 10.1161/CIRCULATIONAHA.115.019355
14. Jones WS, Baumgartner I, Hiatt WR, Heizer G, Conte MS, White CJ, Berger JS, Held P, Katona BG, Mahaffey KW, Norgren L, Blomster J, Millegård M, Reist C, Patel MR, Fowkes FG, International Steering Committee and Investigators of the EUCLID Trial Ticagrelor compared with clopidogrel in patients with prior lower extremity revascularization for peripheral artery disease. Circulation 2017 135 241 250. doi: 10.1161/CIRCULATIONAHA.116.025880
15. Tendera M, Aboyans V, Bartelink ML, Baumgartner I, Clément D, Collet JP, Cremonesi A, De Carlo M, Erbel R, Fowkes FG, Heras M, Kownator S, Minar E, Ostergren J, Poldermans D, Riambau V, Roffi M, Röther J, Sievert H, van Sambeek M, Zeller T, European Stroke Organisation; ESC Committee for Practice Guidelines ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011 32 2851 2906. doi: 10.1093/eurheartj/ehr211
16. Alonso-Coello P, Bellmunt S, McGorrian C, Anand SS, Guzman R, Criqui MH, Akl EA, Olav Vandvik P, Lansberg MG, Guyatt GH, Spencer FA, American College of Chest P Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012 141 e669S e690S
17. Conte MS, Pomposelli FB, Clair DG, Geraghty PJ, McKinsey JF, Mills JL, Moneta GL, Murad MH, Powell RJ, Reed AB, Schanzer A, Sidawy AN, Society for Vascular Surgery Lower Extremity Guidelines Writing Group; Society for Vascular Surgery Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. J Vasc Surg 2015 61 3 Suppl 2S 41S. doi: 10.1016/j.jvs.2014.12.009
18. Davì G, Patrono C, Platelet activation and atherothrombosis. N Engl J Med 2007 357 2482 2494. doi: 10.1056/NEJMra071014
19. Gurbel PA, Tantry US, Antiplatelet and anticoagulant agents in heart failure: current status and future perspectives. J Am Coll Cardiol Heart Fail 2014 2 1 14. doi: 10.1016/j.jchf.2013.07.007
20. Baumann F, Fust J, Engelberger RP, Hügel U, Do DD, Willenberg T, Baumgartner I, Diehm N, Early recoil after balloon angioplasty of tibial artery obstructions in patients with critical limb ischemia. J Endovasc Ther 2014 21 44 51. doi: 10.1583/13-4486MR.1
21. Rodriguez A, Santaera O, Larribeau M, Sosa MI, Palacios IF, Early decrease in minimal luminal diameter after successful percutaneous transluminal coronary angioplasty predicts late restenosis. Am J Cardiol 1993 71 1391 1395
22. Nakatani M, Takeyama Y, Shibata M, Yorozuya M, Suzuki H, Koba S, Katagiri T, Mechanisms of restenosis after coronary intervention: difference between plain old balloon angioplasty and stenting. Cardiovasc Pathol 2003 12 40 48
23. Gibbons GH, Dzau VJ, The emerging concept of vascular remodeling. N Engl J Med 1994 330 1431 1438. doi: 10.1056/NEJM199405193302008
24. Mitra AK, Gangahar DM, Agrawal DK, Cellular, molecular and immunological mechanisms in the pathophysiology of vein graft intimal hyperplasia. Immunol Cell Biol 2006 84 115 124. doi: 10.1111/j.1440-1711.2005.01407.x
25. Perktold K, Leuprecht A, Prosi M, Berk T, Czerny M, Trubel W, Schima H, Fluid dynamics, wall mechanics, and oxygen transfer in peripheral bypass anastomoses. Ann Biomed Eng 2002 30 447 460
26. Jang Y, Guzman LA, Lincoff AM, Gottsauner-Wolf M, Forudi F, Hart CE, Courtman DW, Ezban M, Ellis SG, Topol EJ, Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995 92 3041 3050
27. Huynh TT, Davies MG, Thompson MA, Ezekowitz MD, Hagen P, Annex BH, Local treatment with recombinant tissue factor pathway inhibitor reduces the development of intimal hyperplasia in experimental vein grafts. J Vasc Surg 2001 33 400 407
28. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, Zeller T, Roubin GS, Burket MW, Khatib Y, Snyder SA, Ragheb AO, White JK, Machan LS, Zilver PTX Investigators Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv 2011 4 495 504. doi: 10.1161/CIRCINTERVENTIONS.111.962324
29. Biondi-Zoccai GG, Sangiorgi G, Lotrionte M, Feiring A, Commeau P, Fusaro M, Agostoni P, Bosiers M, Peregrin J, Rosales O, Cotroneo AR, Rand T, Sheiban I, Infragenicular stent implantation for below-The-knee atherosclerotic disease: clinical evidence from an international collaborative meta-Analysis on 640 patients. J Endovasc Ther 2009 16 251 260. doi: 10.1583/09-2691.1
30. Evans BC, Hocking KM, Osgood MJ, Voskresensky I, Dmowska J, Kilchrist KV, Brophy CM, Duvall CL, MK2 inhibitory peptide delivered in nanopolyplexes prevents vascular graft intimal hyperplasia. Sci Transl Med 2015 7 291ra95. doi: 10.1126/scitranslmed.aaa4549
31. Ge JJ, Zhao ZW, Zhou ZC, Wu S, Zhang R, Pan FM, Abendroth DK, p38 MAPK inhibitor, CBS3830 limits vascular remodelling in arterialised vein grafts. Heart Lung Circ 2013 22 751 758. doi: 10.1016/j.hlc.2013.02.006
32. Iftikhar O, Oliveros K, Tafur AJ, Casanegra AI, Prevention of femoropopliteal in-stent restenosis with cilostazol: a meta-Analysis. Angiology 2016 67 549 555. doi: 10.1177/0003319715604768
33. Warner CJ, Greaves SW, Larson RJ, Stone DH, Powell RJ, Walsh DB, Goodney PP, Cilostazol is associated with improved outcomes after peripheral endovascular interventions. J Vasc Surg 2014 59 1607 1614. doi: 10.1016/j.jvs.2013.11.096
34. Patel MR, Conte MS, Cutlip DE, Dib N, Geraghty P, Gray W, Hiatt WR, Ho M, Ikeda K, Ikeno F, Jaff MR, Jones WS, Kawahara M, Lookstein RA, Mehran R, Misra S, Norgren L, Olin JW, Povsic TJ, Rosenfield K, Rundback J, Shamoun F, Tcheng J, Tsai TT, Suzuki Y, Vranckx P, Wiechmann BN, White CJ, Yokoi H, Krucoff MW, Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC). J Am Coll Cardiol 2015 65 931 941. doi: 10.1016/j.jacc.2014.12.036
35. Conte MS, Geraghty PJ, Bradbury AW, Hevelone ND, Lipsitz SR, Moneta GL, Nehler MR, Powell RJ, Sidawy AN, Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia. J Vasc Surg 2009 50 1462.e1 1473.e1. doi: 10.1016/j.jvs.2009.09.044
36. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H, Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011 123 2736 2747. doi: 10.1161/CIRCULATIONAHA.110.009449
37. Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, Sandercock PA, Fox KA, Lowe GD, Murray GD, Aspirin for Asymptomatic Atherosclerosis Trialists Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010 303 841 848. doi: 10.1001/jama.2010.221
38. Hiatt WR, Fowkes FG, Heizer G, Berger JS, Baumgartner I, Held P, Katona BG, Mahaffey KW, Norgren L, Jones WS, Blomster J, Millegård M, Reist C, Patel MR, EUCLID Trial Steering Committee and Investigators Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med 2017 376 32 40. doi: 10.1056/NEJMoa1611688
39. Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA, CHARISMA Investigators Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J 2009 30 192 201. doi: 10.1093/eurheartj/ehn534
40. CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996 348 1329 1339
41. Bonaca MP, Bhatt DL, Storey RF, Steg PG, Cohen M, Kuder J, Goodrich E, Nicolau JC, Parkhomenko A, López-Sendón J, Dellborg M, Dalby A, Špinar J, Aylward P, Corbalán R, Abola MT, Jensen EC, Held P, Braunwald E, Sabatine MS, Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. J Am Coll Cardiol 2016 67 2719 2728. doi: 10.1016/j.jacc.2016.03.524
42. Antithrombotic Trialists' Collaboration Collaborative meta-Analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002 324 71 86
43. Catalano M, Born G, Peto R, Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med 2007 261 276 284
44. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Shepherd J, Macfarlane P, Morris A, Jung R, Kelly C, Connacher A, Peden N, Jamieson A, Matthews D, Leese G, McKnight J, O'Brien I, Semple C, Petrie J, Gordon D, Pringle S, MacWalter R, Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008 337 a1840
45. Berger JS, Krantz MJ, Kittelson JM, Hiatt WR, Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-Analysis of randomized trials. JAMA 2009 301 1909 1919. doi: 10.1001/jama.2009.623
46. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ, CHARISMA Investigators Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006 354 1706 1717. doi: 10.1056/NEJMoa060989
47. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsén M, PLATO Investigators Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009 361 1045 1057. doi: 10.1056/NEJMoa0904327
48. Patel MR, Becker RC, Wojdyla DM, Emanuelsson H, Hiatt WR, Horrow J, Husted S, Mahaffey KW, Steg PG, Storey RF, Wallentin L, James SK, Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. Eur J Prev Cardiol 2015 22 734 742. doi: 10.1177/2047487314533215
49. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS, PEGASUS-TIMI 54 Steering Committee and Investigators Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015 372 1791 1800. doi: 10.1056/NEJMoa1500857
50. Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LH, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R, Erkan A, Huber K, Hudson MP, Jiang L, Jukema JW, Lewis BS, Lincoff AM, Montalescot G, Nicolau JC, Ogawa H, Pfisterer M, Prieto JC, Ruzyllo W, Sinnaeve PR, Storey RF, Valgimigli M, Whellan DJ, Widimsky P, Strony J, Harrington RA, Mahaffey KW, TRACER Investigators Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012 366 20 33. doi: 10.1056/NEJMoa1109719
51. Jones WS, Tricoci P, Huang Z, Moliterno DJ, Harrington RA, Sinnaeve PR, Strony J, Van de Werf F, White HD, Held C, Armstrong PW, Aylward PE, Chen E, Patel MR, Mahaffey KW, Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). Am Heart J 2014 168 588 596. doi: 10.1016/j.ahj.2014.06.017
52. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA, TRA 2P-TIMI 50 Steering Committee and Investigators Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012 366 1404 1413. doi: 10.1056/NEJMoa1200933
53. Anand S, Yusuf S, Xie C, Pogue J, Eikelboom J, Budaj A, Sussex B, Liu L, Guzman R, Cina C, Crowell R, Keltai M, Gosselin G, Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007 357 217 227
54. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, ROCKET AF Investigators Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011 365 883 891. doi: 10.1056/NEJMoa1009638
55. Jones WS, Hellkamp AS, Halperin J, Piccini JP, Breithardt G, Singer DE, Fox KA, Hankey GJ, Mahaffey KW, Califf RM, Patel MR, Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. Eur Heart J 2014 35 242 249. doi: 10.1093/eurheartj/eht492
56. Collaborative overview of randomised trials of antiplatelet therapy-II Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration. BMJ 1994 308 159 168
57. Robertson L, Ghouri MA, Kovacs F, Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev 2012 8 CD002071
58. Strobl FF, Brechtel K, Schmehl J, Zeller T, Reiser MF, Claussen CD, Tepe G, Twelve-month results of a randomized trial comparing mono with dual antiplatelet therapy in endovascularly treated patients with peripheral artery disease. J Endovasc Ther 2013 20 699 706. doi: 10.1583/13-4275MR.1
59. Iida O, Nanto S, Uematsu M, Morozumi T, Kitakaze M, Nagata S, Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. J Vasc Surg 2008 48 144 149. doi: 10.1016/j.jvs.2008.02.062
60. McCollum C, Alexander C, Kenchington G, Franks PJ, Greenhalgh R, Antiplatelet drugs in femoropopliteal vein bypasses: a multicenter trial. J Vasc Surg 1991 13 150 161
61. Bedenis R, Lethaby A, Maxwell H, Acosta S, Prins MH, Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst Rev 2015 2 CD000535
62. Becquemin JP, Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the leg. N Engl J Med 1997 337 1726 1731
63. Castelli P, Basellini A, Agus GB, Ippolito E, Pogliani EM, Colombi M, Gianese F, Scatigna M, Thrombosis prevention with ticlopidine after femoropopliteal thromboendarterectomy. Int Surg 1986 71 252 255
64. Belch JJ, Dormandy J, Biasi GM, Biasi BM, Cairols M, Diehm C, Eikelboom B, Golledge J, Jawien A, Lepäntalo M, Norgren L, Hiatt WR, Becquemin JP, Bergqvist D, Clement D, Baumgartner I, Minar E, Stonebridge P, Vermassen F, Matyas L, Leizorovicz A, CASPAR Writing Committee Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg 2010 52 825 833. doi: 10.1016/j.jvs.2010.04.027
65. Burdess A, Nimmo AF, Garden OJ, Murie JA, Dawson AR, Fox KA, Newby DE, Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia. Ann Surg 2010 252 37 42. doi: 10.1097/SLA.0b013e3181e40dde
66. Arfvidsson B, Lundgren F, Drott C, Scherstén T, Lundholm K, Influence of coumarin treatment on patency and limb salvage after peripheral arterial reconstructive surgery. Am J Surg 1990 159 556 560
67. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial. Lancet 2000 355 346 351
68. Sarac TP, Huber TS, Back MR, Ozaki CK, Carlton LM, Flynn TC, Seeger JM, Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure. J Vasc Surg 1998 28 446 457
69. Johnson WC, Williford WO, Department of Veterans Affairs Cooperative Study #362 Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. J Vasc Surg 2002 35 413 421
70. Monaco M, Di Tommaso L, Pinna GB, Lillo S, Schiavone V, Stassano P, Combination therapy with warfarin plus clopidogrel improves outcomes in femoropopliteal bypass surgery patients. J Vasc Surg 2012 56 96 105. doi: 10.1016/j.jvs.2012.01.004
71. Jivegård L, Drott C, Gelin J, Groth O, Hensäter M, Jensen N, Johansson G, Konrad P, Lindberg B, Lindhagen A, Lundqvist B, Oden A, Smith L, Stenberg B, Thornell E, Wingren U, Ortenwall P, Effects of three months of low molecular weight heparin (dalteparin) treatment after bypass surgery for lower limb ischemia-A randomised placebo-controlled double blind multicentre trial. Eur J Vasc Endovasc Surg 2005 29 190 198. doi: 10.1016/j.ejvs.2004.11.011
72. Kittelson JM, Steg PG, Halperin JL, Goldenberg NA, Schulman S, Spyropoulos AC, Kessler CM, Turpie AG, Cutler NR, Hiatt WR, Antithrombotic Trials Leadership and Steering (ATLAS) Group Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation. Thromb Haemost 2016 116 544 553. doi: 10.1160/TH15-12-1000
73. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A, Antithrombotic Trialists' (ATT) Collaboration Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-Analysis of individual participant data from randomised trials. Lancet 2009 373 1849 1860. doi: 10.1016/S0140-6736(09)60503-1
74. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH, 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011 124 e574 e651. doi: 10.1161/CIR.0b013e31823ba622
75. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ, Members AATF 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014 130 e344 e426
76. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O'Gara PT, Sabatine MS, Smith PK, Smith SC Jr., 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation 2016 134 e123 e155. doi: 10.1161/CIR.0000000000000404
77. Geisler T, Zürn C, Simonenko R, Rapin M, Kraibooj H, Kilias A, Bigalke B, Stellos K, Schwab M, May AE, Herdeg C, Gawaz M, Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J 2010 31 59 66. doi: 10.1093/eurheartj/ehp402
78. Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF, Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009 119 237 242. doi: 10.1161/CIRCULATIONAHA.108.812636
79. Wallentin L, Varenhorst C, James S, Erlinge D, Braun OO, Jakubowski JA, Sugidachi A, Winters KJ, Siegbahn A, Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008 29 21 30. doi: 10.1093/eurheartj/ehm545
80. Baber U, Mehran R, Sharma SK, Brar S, Yu J, Suh JW, Kim HS, Park SJ, Kastrati A, de Waha A, Krishnan P, Moreno P, Sweeny J, Kim MC, Suleman J, Pyo R, Wiley J, Kovacic J, Kini AS, Dangas GD, Impact of the everolimus-eluting stent on stent thrombosis: a meta-Analysis of 13 randomized trials. J Am Coll Cardiol 2011 58 1569 1577. doi: 10.1016/j.jacc.2011.06.049
81. Schulz-Schüpke S, Byrne RA, Ten Berg JM, Neumann FJ, Han Y, Adriaenssens T, Tölg R, Seyfarth M, Maeng M, Zrenner B, Jacobshagen C, Mudra H, von Hodenberg E, Wöhrle J, Angiolillo DJ, von Merzljak B, Rifatov N, Kufner S, Morath T, Feuchtenberger A, Ibrahim T, Janssen PW, Valina C, Li Y, Desmet W, Abdel-Wahab M, Tiroch K, Hengstenberg C, Bernlochner I, Fischer M, Schunkert H, Laugwitz KL, Schömig A, Mehilli J, Kastrati A, Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) Trial Investigators ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J 2015 36 1252 1263. doi: 10.1093/eurheartj/ehu523
82. Gilard M, Barragan P, Noryani AA, Noor HA, Majwal T, Hovasse T, Castellant P, Schneeberger M, Maillard L, Bressolette E, Wojcik J, Delarche N, Blanchard D, Jouve B, Ormezzano O, Paganelli F, Levy G, Sainsous J, Carrie D, Furber A, Berland J, Darremont O, Le Breton H, Lyuycx-Bore A, Gommeaux A, Cassat C, Kermarrec A, Cazaux P, Druelles P, Dauphin R, Armengaud J, Dupouy P, Champagnac D, Ohlmann P, Endresen K, Benamer H, Kiss RG, Ungi I, Boschat J, Morice MC, 6-versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. J Am Coll Cardiol 2015 65 777 786. doi: 10.1016/j.jacc.2014.11.008
83. Colombo A, Chieffo A, Frasheri A, Garbo R, Masotti-Centol M, Salvatella N, Oteo Dominguez JF, Steffanon L, Tarantini G, Presbitero P, Menozzi A, Pucci E, Mauri J, Cesana BM, Giustino G, Sardella G, Second-generation drug-eluting stent implantation followed by 6-versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol 2014 64 2086 2097. doi: 10.1016/j.jacc.2014.09.008
84. Mittleider D, Russell E, Peripheral atherectomy: applications and techniques. Tech Vasc Interv Radiol 2016 19 123 135. doi: 10.1053/j.tvir.2016.04.005
85. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, Machan LS, Snyder SA, O'Leary EE, Ragheb AO, Zeller T, Zilver PTX Investigators Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX Randomized Trial. Circulation 2016 133 1472 1483. doi: 10.1161/CIRCULATIONAHA.115.016900
86. Lammer J, Zeller T, Hausegger KA, Schaefer PJ, Gschwendtner M, Mueller-Huelsbeck S, Rand T, Funovics M, Wolf F, Rastan A, Gschwandtner M, Puchner S, Ristl R, Schoder M, Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease). J Am Coll Cardiol 2013 62 1320 1327. doi: 10.1016/j.jacc.2013.05.079
87. Laird JR, Schneider PA, Tepe G, Brodmann M, Zeller T, Metzger C, Krishnan P, Scheinert D, Micari A, Cohen DJ, Wang H, Hasenbank MS, Jaff MR, IN.PACT SFA Trial Investigators Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of IN.PACT SFA. J Am Coll Cardiol 2015 66 2329 2338. doi: 10.1016/j.jacc.2015.09.063
88. Sobieszczyk P, Eisenhauer A, Management of patients after endovascular interventions for peripheral artery disease. Circulation 2013 128 749 757. doi: 10.1161/CIRCULATIONAHA.113.001560
89. Gremmel T, Xhelili E, Steiner S, Koppensteiner R, Kopp CW, Panzer S, Response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions: differences between peripheral and coronary angioplasty. Atherosclerosis 2014 232 119 124. doi: 10.1016/j.atherosclerosis.2013.10.027
90. Pärsson H, Holmberg A, Siegbahn A, Bergqvist D, Activation of coagulation and fibrinolytic systems in patients with CLI is not normalized after surgical revascularisation. Eur J Vasc Endovasc Surg 2004 27 186 192. doi: 10.1016/j.ejvs.2003.10.015
91. Collins P, Ford I, Greaves M, Macaulay E, Brittenden J, Surgical revascularisation in patients with severe limb ischaemia induces a pro-thrombotic state. Platelets 2006 17 311 317. doi: 10.1080/09537100600746540
92. Girolami B, Bernardi E, Prins MH, ten Cate JW, Prandoni P, Simioni P, Andreozzi GM, Girolami A, Büller HR, Antiplatelet therapy and other interventions after revascularisation procedures in patients with peripheral arterial disease: a meta-Analysis. Eur J Vasc Endovasc Surg 2000 19 370 380. doi: 10.1053/ejvs.1999.1034
93. Maufus M, Pernod G, Antithrombotic therapy after infrainguinal bypass. J Vasc Surg 2014 60 1367 1375. doi: 10.1016/j.jvs.2014.07.105
94. Lassila R, Lepäntalo M, Lindfors O, The effect of acetylsalicylic acid on the outcome after lower limb arterial surgery with special reference to cigarette smoking. World J Surg 1991 15 378 382
95. Geraghty AJ, Welch K, Antithrombotic agents for preventing thrombosis after infrainguinal arterial bypass surgery. Cochrane Database Syst Rev 2011;6:CD000536
96. Jones WS, Mi X, Qualls LG, Turley RS, Vemulapalli S, Peterson ED, Patel MR, Curtis LH, Significant variation in P2Y12 inhibitor use after peripheral vascular intervention in Medicare beneficiaries. Am Heart J 2016 179 10 18
97. Allemang MT, Rajani RR, Nelson PR, Hingorani A, Kashyap VS, Prescribing patterns of antiplatelet agents are highly variable after lower extremity endovascular procedures. Ann Vasc Surg 2013 27 62 67. doi: 10.1016/j.avsg.2012.05.001.